Iloperidone

Limits on what this shows

• Key negative/null findings: In a rat stress-paradigm model, risperidone - a chemically related piperidinyl-benzisoxazole antipsychotic (Tier B for risperidone, Tier C extrapolation for iloperidone) - attenuated rather than caused stress-induced mitochondrial dysfunction and apoptosis: a reverse-direction, protective finding under this framework.
• At-risk subgroups: None established for iloperidone specifically.
• Counter-evidence on record: The disease-intrinsic hypothesis competes directly with any drug-causation claim (confounding by indication is presumed until excluded); the one class-adjacent interventional data point located runs protective, not depleting.

Regulatory status

Not addressed in the FDA label; no mitochondrial-toxicity signal, warning, or monitoring requirement for iloperidone.

Population evidence

Class-level/disease-level only: a 2025 randomized-controlled-trial protocol and a 2026 completed trial report, both titled around mitochondrial dysfunction in schizophrenia and its modulation by atypical antipsychotic drugs generally (Tier C; iloperidone not confirmed in either cohort), plus a narrative review of antipsychotic effects on energy metabolism covering first- and second-generation agents generally.

Mechanism

Hypothesized disease-intrinsic mitochondrial/bioenergetic disturbance in schizophrenia (disease-level, independent of any specific drug); no enzyme-level mechanism specific to iloperidone exists in the literature retrieved this session.

Counter-evidence held on record

Do not present this as iloperidone causing mitochondrial damage. The stronger, better-established association in this literature is between the illness itself and mitochondrial/bioenergetic change, not between this specific drug and such change, and the one relevant class-level interventional study found points toward protection.

Limits on what this shows

• Key negative/null findings: The two iloperidone-specific PubMed hits for "oxidative stress" were analytical-chemistry forced-degradation (stability) studies of the iloperidone molecule itself, not biological oxidative-stress findings in patients, and are excluded from this grading as irrelevant.
• At-risk subgroups: None established for iloperidone.
• Counter-evidence on record: Disease-intrinsic confound presumed until excluded (Hard Rule 6); no iloperidone-attributable data exist in the literature retrieved.

Regulatory status

Not addressed in the FDA label.

Population evidence

A 2013 meta-analysis of oxidative stress in schizophrenia and a 2011 review of oxidative-stress markers in schizophrenia (both disease-level, Tier C); a 2023 "Comparative Analysis of the Pre- and Post-Medication Effects of Antipsychotic Agents on Blood-Based Oxidative Stress Biomarkers" confirms a pre/post-medication, class-level design exists, but its abstract could not be retrieved this session (two attempts blocked by HTTP 429), so direction, magnitude, and which drugs were studied are not confirmed.

Mechanism

Not drug-specific; the general hypothesis involves dopamine metabolism, neuroinflammation, and mitochondrial electron leakage as reactive-oxygen-species sources in schizophrenia, independent of which antipsychotic (if any) a patient is taking.

Counter-evidence held on record

Elevated oxidative-stress markers in schizophrenia research describe the illness, not a confirmed effect of iloperidone. Nothing here supports antioxidant supplementation as a response to taking this drug specifically.

Limits on what this shows

• Key negative/null findings: The 2018 source explicitly frames drug-attribution as "obscure," i.e., not confirmed either way.
• At-risk subgroups: None established for iloperidone specifically.
• Counter-evidence on record: Confounding by indication is the default presumption here and has not been excluded; no iloperidone-specific cohort data exist.

Regulatory status

Not addressed in the FDA label; no copper monitoring requirement.

Population evidence

A 2020 systematic review and meta-analysis of 39 studies (N=5151) reports, quoted directly: "higher levels of copper, lower levels of iron, and lower levels of zinc among patients with schizophrenia vs controls." A 2018 study on serum trace elements and antipsychotic treatment states, quoted directly: "whether such variation is resulted from the antipsychotic treatment remains obscure." A 2000 study found higher serum copper in patients on first-generation depot neuroleptics, but this cohort used typical/first-generation agents - a different pharmacological class from iloperidone's piperidinyl-benzisoxazole, D2/5-HT2A-balanced second-generation profile - so it fails the cohort test for this drug and is excluded from the grading basis (cited in Sources as excluded).

Mechanism

Not established as drug-specific; copper rises with ceruloplasmin as an acute-phase reactant, so elevation can reflect low-grade inflammation rather than a pharmacologic effect of any particular antipsychotic.

Counter-evidence held on record

This describes schizophrenia as a condition, not iloperidone as a drug. Do not present elevated copper as something iloperidone causes, and do not recommend copper-lowering measures or zinc supplementation on this basis (see Overlap map: this entry shares its evidence base with Iron and Zinc below).

Limits on what this shows

• Key negative/null findings: No ferritin, transferrin saturation, or serum iron data for iloperidone-treated patients were found this session.
• At-risk subgroups: None established for iloperidone specifically.
• Counter-evidence on record: Confounding by indication applies to the disease-level finding. The iron-deficiency explanation for the restless-legs signal is unfalsifiable as framed (no named, measured functional marker), and the drug's own intended dopaminergic pharmacology already plausibly explains the movement-disorder signal without invoking any nutrient.

Regulatory status

The FDA label lists restless legs syndrome as a rare postmarketing adverse event; there is no iron or ferritin monitoring requirement.

Population evidence

The same 2020 meta-analysis of 39 studies (N=5151), quoted directly: "lower levels of iron... among patients with schizophrenia vs controls" (disease-level, Tier C, see Overlap map with Copper and Zinc).

Mechanism

Not drug-specific for the disease-level iron finding. For the restless-legs signal specifically, the more parsimonious, better-evidenced mechanism is iloperidone's own D2-dopamine-receptor antagonism (Ki 6.3 nM, Tier A, label Section 12.2) - the same mechanism underlying its separately documented, dose-related akathisia (4.4% vs 0% placebo at 24 mg/day bipolar-mania dosing).

Counter-evidence held on record

Do not use iloperidone's postmarketing restless-legs signal to justify iron supplementation. No iron-status marker has been measured in this population, and the more parsimonious, already-documented explanation is the drug's own dopamine-antagonist mechanism (see Fails verification below).

Limits on what this shows

• Key negative/null findings: A direct "iloperidone microbiota" PubMed search returned a bot-verification challenge page rather than a usable result this session - an inconclusive block, not a confirmed absence of literature.
• At-risk subgroups: None established for iloperidone specifically.
• Counter-evidence on record: Class-level title/snippet evidence does not specify which second-generation antipsychotics were actually studied, so the cohort test is only partially satisfied; iloperidone is a defensible SGA-class member by mechanism and chemical class, but direct confirmation of its inclusion is unavailable.

Regulatory status

Not addressed in the FDA label. The label does document dose-related dry mouth (8-10% vs 1-2% placebo), nausea, and diarrhea (Tier A, drug-specific), which are consistent with but do not prove a microbiome-level effect.

Population evidence

A 2024 systematic review, "Effects of antipsychotics on the gastrointestinal microbiota," quoted directly: "increasing evidence has also indicated that its use impacts gut microbiota (GM)." A 2023 review on second-generation antipsychotics and lipid metabolism via the gut microbiota, quoted directly: "SGA treatment may alter the abundance and composition of the gut microbiota." Neither excerpt names iloperidone specifically, and which individual drugs were in each review's source studies could not be confirmed this session.

Mechanism

A plausible indirect route exists via iloperidone's own mild GI adverse-effect profile (dry mouth, altered GI transit reflected in diarrhea/nausea rates), which could secondarily affect microbial composition, though this specific causal chain has not been tested for iloperidone.

Counter-evidence held on record

This is class-level plausibility, not iloperidone-specific evidence. No probiotic or microbiome-targeted supplement is recommended on this basis.

Limits on what this shows

• Key negative/null findings: No iron, ferritin, transferrin saturation, or MCV data are reported anywhere in the label; the simultaneous, multi-analyte decline (cells and proteins together) is not the isolated red-cell pattern expected of a true iron- or B12-deficiency anemia.
• At-risk subgroups: Higher-dose bipolar-mania regimens (up to 24 mg/day) showed a larger effect (3.5%) than schizophrenia dosing (1.0%); patients already close to anemia or hypoalbuminemia thresholds.
• Counter-evidence on record: No dedicated iloperidone hematology or iron-status study was located this session (search attempted; see Sources), so a true iron-deficiency mechanism can be neither confirmed nor excluded by the data in hand - this is exactly the circulating-vs-functional-marker gap this protocol treats as unfalsifiable if asserted as iron deficiency (see the Fails verification entry below).

Regulatory status

Documented in the FDA label's laboratory-abnormalities data; no black-box warning or mandated CBC monitoring specifically for this finding.

Population evidence

Short-term, placebo-controlled trials: hematocrit reduced ~1.0% vs placebo in schizophrenia dosing (10-24 mg/day) and ~3.5% vs placebo in bipolar-mania dosing (up to 24 mg/day); the label reports these alongside parallel decreases in hemoglobin, white blood cells, total protein, and albumin (Tier A, regulatory label, iloperidone itself).

Mechanism

Not elaborated in the label beyond description; plausibly related to plasma-volume expansion, consistent with iloperidone's high-affinity alpha1-adrenergic antagonism (Ki 0.36 nM), the same receptor mechanism the label names for its orthostatic-hypotension effect.

Counter-evidence held on record

This is a dilutional hematologic pattern, not evidence of iron, B12, or other nutrient-specific depletion. Do not use this entry to justify iron or hematinic supplementation; the co-occurring decline in total protein and albumin points to a plasma-volume change, not reduced nutrient stores.

Limits on what this shows

• Key negative/null findings: None iloperidone-specific found.
• At-risk subgroups: None established for iloperidone.
• Counter-evidence on record: Same disease-intrinsic confound as Mitochondrial burden; no drug-attributable ATP measurement exists in the literature retrieved.

Regulatory status

Not addressed in the FDA label.

Population evidence

Same three class-level/disease-level sources cited under Mitochondrial burden; the energy-metabolism review specifically frames "altered bioenergetic pathways" as its subject (Tier C, see Overlap map - this is not independent confirmation beyond that entry).

Mechanism

Downstream of any electron-transport-chain disturbance implicated above; no iloperidone-specific enzymatic step identified in this session's research.

Counter-evidence held on record

This is not independent confirmation of an ATP-specific drug effect; it rests on the same underlying disease-level bioenergetics literature cited under Mitochondrial burden (see Overlap map). No CoQ10, carnitine, or B-vitamin supplementation is supported by this entry.